Background and aims: The clinical value of gastrin-releasing peptide precursor (Pro-GRP) in small cell lung cancer (SCLC) remains controversial. This meta-analysis aimed to investigate the prognostic and recurrence-related significance of Pro-GRP in SCLC. Methods: The association between Pro-GRP expression and clinical significance was measured by odds ratios (ORs) using Review Manager. Pooled odds ratios (ORs) of Pro-GRP and survival time were calculated to measure the predictive value of the Pro-GRP level with respect to prognosis. Results: The serum levels of Pro-GRP were significantly associated with chemotherapy response, survival time, and the disease stage. After chemotherapy, patients with complete remission (CR), patients with partial remission (PR) and the effective group, which included CR+PR, PR+CR+SD, and PR+NC, showed a marked decrease in Pro-GRP concentrations (P<0.05). Compared with other chemotherapy responses, the levels of Pro-GRP in the above groups of patients showed significant changes before and after chemotherapy. The serum Pro-GRP or Pro-GRP levels in the progressive disease (PD) group were significantly lower than the post-treatment levels (P<0.00001), while the Pro-GRP concentration showed no significant difference in the stable disease (SD) group (P=0.76). In studies evaluating the survival time, Pro-GRP levels were associated with the survival time (P<0.00001). When the level of Pro-GRP was higher, the survival time was shorter, but there was no statistically significant difference for six months of survival time (P=0.29). The survival time for patients with low Pro-GRP levels was longer than for patients with elevated levels (12 months: P=0.0003; 24 months: P<0.00001). A significant difference between the limited disease (LD) group and the extensive disease (ED) group was found. The mean serum levels of Pro-GRP were significantly higher in ED patients than in LD patients (P=0.02). Conclusion: Pro-GRP has become a new blood biomarker and can be used to monitor the prognosis and progression of SCLC.
[1]Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, 274 Zhi Jiang Rd, Shanghai 200071, Peoples R China.
[2]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Tradit Chinese & Western Med, 507 Zheng Min Rd, Shanghai 200433, Peoples R China.
(8.0+极速模式)